Deka Biosciences is pioneering a transformative approach to immunotherapy through its innovative Diakine™ platform, which focuses on developing personalized treatments for cancer and inflammatory diseases. This platform uniquely combines two anti-inflammatory cytokines for treating inflammatory conditions and merges immune-stimulating cytokines with anti-inflammatory ones for cancer therapy. By targeting specific tissues affected by disease, the Diakine™ platform aims to enhance the efficacy of treatments while minimizing side effects, thereby offering a tailored therapeutic strategy based on individual patient immune responses.

The company's pipeline includes a range of investigational therapies designed to address various conditions, including inflammatory bowel disease, psoriasis, and multiple types of cancer. Each Diakine™ product is characterized by its specific combination of cytokines and targeted delivery methods, such as subcutaneous administration or intratumoral injection. This strategic focus on cytokine therapy not only aims to improve disease control but also represents a next-generation approach to harnessing the immune system's potential in combating complex health challenges.

United States

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.  Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Deka Biosciences

Company Details